당뇨병 치료제 시장 규모, 점유율, 성장 분석 : 당뇨병 유형별, 약물 유형별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Global Diabetes Therapeutics Market size was valued at USD 71.2 billion in 2023 and is poised to grow from USD 76.11 billion in 2024 to USD 129.8 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global diabetes therapeutics market is experiencing robust growth due to increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population worldwide creates significant market opportunities, as older individuals are more susceptible to diabetes. Additionally, urbanization and lifestyle changes are contributing to heightened diabetes risks, further driving market expansion. Enhanced awareness and early detection are motivating individuals to seek diabetes therapies. The trend towards personalized and precision medicine is fostering tailored treatment solutions that enhance effectiveness. Technological integration, including AI, machine learning, IoT, and blockchain, is revolutionizing drug discovery and disease management. These innovations provide real-time monitoring and insights, thereby promoting better treatment adherence and improving overall patient outcomes in diabetes care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The global demand for diabetes therapeutics is being significantly driven by the rising prevalence of both type 1 and type 2 diabetes. This demand is further amplified by an aging population, as older individuals are more susceptible to developing diabetes. Additionally, the escalating rates of obesity, coupled with sedentary lifestyles and unhealthy dietary choices, contribute to market growth by leading to higher levels of insulin resistance and various metabolic disorders. These factors collectively underscore the urgent need for effective diabetes management solutions, propelling the expansion of the diabetes therapeutics market on a worldwide scale.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces notable challenges due to the substantial expenses associated with the ongoing management of both type 1 and type 2 diabetes. Effective treatment often necessitates a lifelong commitment to purchasing insulin, medications, therapies, and glucose monitoring equipment, which can pose a significant financial burden. Individuals lacking adequate health insurance or access to quality healthcare services often struggle to afford necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, the escalating costs associated with novel biologics and personalized medicine are creating barriers to innovation within the diabetes therapeutics sector, hindering advancements and limiting access for patients.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is witnessing a significant trend towards the adoption of personalized and precision medicine, focusing on individualized treatment approaches that cater to distinct genetic profiles, metabolic variations, and lifestyle factors. This shift aims to address the root causes of diabetes by improving insulin sensitivity and overall therapeutic efficacy. With advancements in biotechnology and a growing emphasis on tailored healthcare solutions, these innovative therapies are becoming increasingly accessible and cost-effective, fostering greater acceptance and adherence among patients. As a result, this trend is poised to reshape the landscape of diabetes management by enhancing treatment outcomes and patient experiences.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2025-2032)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations